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Abstract
To optimise the efficiency of cell machinery, cells can use the same protein (often called a hub protein) to participate in
different cell functions by simply changing its target molecules. There are large data sets describing protein-protein
interactions (‘‘interactome’’) but they frequently fail to consider the functional significance of the interactions themselves.
We studied the interaction between two potential hub proteins, ICln and 4.1R (in the form of its two splicing variants 4.1R80
and 4.1R135), which are involved in such crucial cell functions as proliferation, RNA processing, cytoskeleton organisation
and volume regulation. The sub-cellular localisation and role of native and chimeric 4.1R over-expressed proteins in human
embryonic kidney (HEK) 293 cells were examined. ICln interacts with both 4.1R80 and 4.1R135 and its over-expression
displaces 4.1R from the membrane regions, thus affecting 4.1R interaction with ß-actin. It was found that 4.1R80 and 4.1R135
are differently involved in regulating the swelling activated anion current (ICl,swell) upon hypotonic shock, a condition under
which both isoforms are dislocated from the membrane region and thus contribute to ICl,swell current regulation. Both 4.1R
isoforms are also differently involved in regulating cell morphology, and ICln counteracts their effects. The findings of this
study confirm that 4.1R plays a role in cell volume regulation and cell morphology and indicate that ICln is a new negative
regulator of 4.1R functions.
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Introduction
ICln [1] is a ubiquitously expressed and highly conserved [2]
26 kDa protein, whose knock-out in mice is lethal [3]. This is
consistent with its essential role in one or more basic cell processes,
and it has therefore been proposed to be a connector hub [4] of
such diverse cell functions as ion permeation [5], cytoskeletal
organisation [6–9] and RNA processing [10].
It mainly localises in the cytoplasm, but it is also present in the
nucleus [6] and in membrane regions upon hypotonic stimulation
[11]. In the cytoplasm, ICln acts as a chaperone assembly factor
that is involved in the formation of small nuclear ribonucleopro-
teins (snRNPs) [12,13]. Its hypotonically induced shift towards the
membrane area plays a role in activating the anion current that is
activated upon cell swelling (ICl,swell) [11,14,15], but the mecha-
nism underlying this effect is unclear. The ICln binding/
unbinding regulation of cytoskeletal proteins may be an important
step in the modulation of channel/transporter function because
ICln interacts with actin [6,7] and, in renal collecting duct cells,
this interaction increases after cell swelling [14].
ICln also interacts with the multifunctional 4.1R cytoskeletal
protein [8,16] but the functional role of this interaction has not yet
been investigated. The finding that 4.1R-null mouse erythrocytes
are characterised by cell dehydration due to the hyperactivity of
NHE1 [17,18], the ubiquitous Na+/H+ exchanger that is activated
by cell shrinkage and inhibited by cell swelling [19,20], indicates
that 4.1R protein plays a role in cell volume regulation.
Endogenous and transiently transfected 4.1R isoforms have
been detected in the cytoplasm, nucleus and membrane regions of
nucleated cells [21–25]. The presence of 4.1R proteins in
membrane regions is crucial as they regulate the abundance and
function of transmembrane structural proteins [26], receptors
[17,25,27], transporters [28,29] and channels [30] by acting as
membrane hub proteins [31].
In erythroid and non-erythroid cells, multiple isoforms of 4.1R
are often simultaneously expressed as a result of three distinct
mechanisms: the alternative splicing of pre-mRNA [32–35]; the
presence of an internal ribosome entry site (IRES) that allows the
translation of different isoforms from different translation-initia-
tion codons (ATG1, ATG2 and probably ATG3) [22,36] from a
single mRNA [37]; and post-translational modifications [24,38–
41]. The first two mechanisms produce 4.1R isoforms with
different exon compositions: the 135 kD (4.1R135), 80 kD (4.1R80)
and 60 kD isoforms (4.1R60). All isoforms share highly conserved
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domains: the 4.1 and ezrin/radixin/moesin (FERM) domain, the
spectrin-actin binding domain (SABD), and the C-terminal
domain (CTD).
The selective expression of alternatively spliced mRNA seems to
be developmentally regulated during cell maturation/differentia-
tion [22,33,42–44], and influences 4.1R intracellular localisation
and function [29,35,36,45]. However, the functional differences
between these isoforms and the functional need to express so many
apparently redundant proteins have not yet been fully elucidated.
For this reason, identifying the cell mechanisms responsible for the
intracellular localisation of 4.1R and its compartmentalised
interactions may therefore also have considerable implications
for the study of its functions.
We examined the intracellular localisation and function of
4.1R80 and 4.1R135 in a nucleated human cell line under basal
conditions and during hypotonic cell swelling. The only difference
between the two isoforms is the presence of the 209 N-terminal
amino acids of the headpiece domain coded by AUG-1 in 4.1R135.
ICln interacts with both isoforms and, when over-expressed,
promotes the displacement of 4.1R from the membrane region
and decreases the interaction between 4.1R and subcortical F-
actin.
The two isoforms differently affect ICl,swell activation upon cell
swelling and, during hypotonic stimulation, the amount of 4.1R in
the membrane region decreases. Moreover, 4.1R over-expression
induces cell spreading and the emission of filopodia, an effect that
can be reverted by ICln over-expression.
Our findings strongly suggest a new role for ICln as a regulator
of 4.1R localisation and function, and confirm that 4.1R plays a
role in cell volume regulation.
Materials and Methods
Plasmids and transfection
All of the DNA constructs were confirmed by sequencing. The
cDNAs corresponding to the human open reading frame (ORF) of
4.1R80 and 4.1R135 were obtained by means of RT-PCR from
HEK (human embryonic kidney) cells (LGC Standards S.r.l.,
Italy). The only difference between the two DNAs was the
presence (4.1R135) or absence (4.1R80) of the 209 N-terminal
amino acids of the headpiece (HP) domain. The exon organisation
was the same as that reported for isoforms 4.1R135 and 4.1R80 in
erythroid cells [22]: i.e. both isoforms lacked exons 13–14 (human
gene EBP41, NCBI Reference Sequence:XP_005245821 for
4.1R135 and GenBank refrence sequence AAH96105.2 for
4.1R80). The 4.1R80 and 4.1R135 cDNAs were sub-cloned into
pEYFP-C1 vectors (Y-4.1R80, Y-4.1R135) (Clontech, Mountain
View, CA, USA) in order to express YFP-tagged proteins
respectively C-terminally (C-t) or N-terminally (N-t), and in the
pIRES2-EGFP (4.1R80/135-IRES-GFP) bicistronic vector (Clon-
tech), in order to express the chosen and the fluorescent protein as
two distinct polypeptides. All vector variants expressing 4.1R135
were obtained by additionally mutating the ATG2 codon in exon
4 into GTG, using the Quickchange Site-Directed Mutagenesis kit
(Agilent Technologies Italia S.p.A., Milan, Italy), to prevent the
production of 4.1R80 from 4.1R135, promoted by the presence of
an internal ribosome entry site (IRES) between ATG1 and ATG2
[37]. Similarly, pECFP-C1 containing the ORF of hICln (human
gene CLNS1A, NCBI Reference Sequence: NP_001284.1), C-
ICln, or the ORF of a truncated ICln (aa 1-102, C-IClnT), were
used to express CFP-ICln chimeras. The ORFs for ICln was also
inserted in the pFLAG CMV4 vector (Sigma-Aldrich S.r.l., Milan,
Italy) in order to obtain the FLAG C-t tagged ICln protein
(FLAG-ICln), and in the pIRES2-dsREDexpress (ICln-IRES-
dsRED) bicistronic vector (Clontech). The cDNA for the human
b-actin (human gene ACTB, GenBank reference sequence:
BC016045.1) ORF was inserted into the pECFP-C1 vector in
order to obtain the C-bactin vector. The ptdTomato-N1 vector
(Clontech) was used in the siRNA experiments to express the
Tomato protein; the vector is designed with two copies of the
Tomato coding region linked together to allow intramolecular
dimerization (tdTomato).
HEK cells were transiently transfected 24 hours post-seeding,
and then used for experiments 24 or 48 hours post-transfection
depending on the experimental protocol. In the co-transfection
experiments, each vector was equimolar in the transfection mix.
Cell culture
Human embryonic kidney (HEK) 293T cells were cultured in
Eagle’s Minimum Essential Medium (EMEM, Sigma, Italy)
supplemented with 10% Fetal Bovine Serum (FBS, Lonza S.r.l.,
Milan, Italy), 1 mM sodium pyruvate, 2 mM L-glutamine,
0.1 mM non essential aminoacids, 100 U/ml penicillin, 100 mg/
ml streptomycin (Sigma, Italy). Cell cultures were maintained at
37uC with 5% CO2 and passaged every 3–4 days.
Patch-clamp experiments
The patch-clamp experiments were performed in whole-cell
configuration using HEK cells transiently transfected with the
bicistronic vector pIRES2-EGFP expressing a 4.1R isoform
(pIRES2-EGFP-4.1R135, pIRES2-EGFP-4.1R80). The pIRES2-
EGFP vector, which expresses only EGFP, was used as control.
The pipette solution contained (mM) 125 CsCl, 11 EGTA, 5
MgCl2, 2 Mg-ATP, 50 raffinose and 10 HEPES (pH 7.2, 336
mOsm); the hypertonic bath solution contained (mM) 125 NaCl,
2.5 CaCl2, 2.5 MgCl2, 100 mannitol and 10 HEPES (pH 7.4, 375
mOsm), and the hypotonic bath solution contained (mM) 125
NaCl, 2.5 CaCl2, 2.5 MgCl2 and 10 HEPES (pH 7.4, 275 mOsm).
All of the experiments were performed at room temperature.
The pipettes were pulled from borosilicate glass capillaries and
had a resistance of 3–5 MV after fire polishing. Seal resistances
were typically between 3 and 10 GV. The currents were recorded
using an EPC9 amplifier (HEKA, Lambrecht/Pfalz Germany) and
low-pass filtered at 2.9 kHz. The data were analysed using Pulse/
Pulsefit software (HEKA). The bath was grounded by means of an
Ag/AgCl electrode immersed in the bath solution. The GFP-
positive cells were identified immediately before cell patching
using a fluorescence-equipped inverted microscope (ECLIPSE TS
100, Nikon Instruments S.p.A. Campi Bisenzio, Florence, Italy).
Pipette and whole-cell capacitance and series resistance compen-
sations were made before the recording. I-V relationships were
obtained with a step-protocol, by averaging the currents generated
by pulsing (0.5 s) from -100 mV to +100 mV, with step increments
of 20 mV; the holding voltage between pulses was 0 mV. The
currents were normalised to cell membrane capacitance, and
expressed as current density (pA/pF). In order to construct time
courses of current activation, current amplitude was measured at a
constant potential of +40 mV every 10 s until 10 min after
hypotonic replacement. Membrane capacitance did not change
during each experiment, and was not affected by the clone
transfections.
FRET
The 4.1R/ICln interaction FRET experiments were performed
24 hours after transfection using living cells kept at 37uC with CFP
(cyan fluorescent protein) as the donor and YFP (yellow fluorescent
protein) as the acceptor molecule. The experiments were carried
out using cells kept in a slightly hypertonic extracellular solution
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(in mM: NaCl 90, KCl 5, CaCl2 2, MgCl2 2, glucose 5, HEPES 10
and mannitol 100, 317 mOsm, pH 7.4), or after exposure to a
hypotonic extracellular solution obtained by omitting mannitol
from the hypertonic solution.
In the case of the 4.1R/ß-actin interaction FRET experiments,
the cells were fixed in 4% paraformaldehyde (PFA) in PBS (in
mM: 137 NaCl, 2.7 KCl, 1.8 KH2PO4, 10 Na2HPO4, pH 7.4) for
10 min, and kept in PBS during the confocal acquisitions.
The sensitised emission (Fsen) and NFRET indices (Fsen
normalised by the acceptor emission) were calculated according
to [46].
FRET efficiency (FRETeff) was measured using acceptor
photobleaching [47]. The images were acquired by means of a
Leica TCS SP5 confocal microscope (Leica Microsystems GmbH,
Wetzlar Germany). In order to avoid the possible diffusion of
fluorescent protein in and out of the region of interest (ROI)
during the photobleaching of live cells, the whole of the cell under
examination was bleached. The images were acquired using an
HCX PL APO 63x/1.4 OIL objective (Leica Microsystems
GmbH) and a scan speed of 700 Hz.
FRETeff was then evaluated using the FRETcalc ImageJ plugin
[48] as previously reported [49].
Confocal microscopy
The images of over-expressed YFP-tagged 4.1R and CFP-
tagged ICln were acquired 24 hours post-transfection using a
confocal microscope equipped with an HCX PL APO 40x/1.25
OIL objective (Leica Microsystems GmbH). During the acquisi-
tion, the living HEK cells were kept at 37uC in DPBS (PBS
supplemented with 1 mM CaCl2, 0.5 mM MgCl2, 25 mM
glucose, pH 7.4).
The confocal imaging of the co-localisation experiments
involved living cells kept at 37uC in the microscope incubator
24 hours after transfection. CFP-mem (Cm) was used as a
membrane marker, and Pearson and Manders coefficients were
calculated from the whole-cell Z-stacks acquired using a Leica
TCS SP5 confocal microscope equipped with a resonant scanner
and an HCX PL APO 63x/1.4 OIL objective (scan speed
8000 Hz, pixel size 98.41698.416250 nm). The same fields were
acquired in a hypertonic extracellular solution (317 mOsm), and
after 5 and 10 minutes of hypotonic substitution (217 mOsm). The
co-localisation analyses were made using the ImageJ JACoP plug-
in [50] on the entire stacks after the application of a filter
(Gaussian Blur) in order to remove noise. To select the
fluorescence signal associated with the plasma membrane,
appropriate thresholds for each channel were applied and kept
constant throughout the analysis of each cell (hyper, hypo 59, hypo
109).
STED microscopy
The YFP signal of cells over-expressing a membrane marker
(YFP-mem, Clontech) and the 4.1R135 protein was acquired using
the confocal or gated-STED module of a Leica TCS SP8
microscope (Leica Microsystems GmbH, Wetzlar, Germany)
equipped with an HCX PL APO 100x/1.4 OIL STED ORANGE
objective, a white light laser (WLL) source, and a 592 nm
depletion laser. The images were acquired using hybrid detectors
with a pixel size of 20.7 nm and, in the case of g-STED, a time-
gate between 1.5 and 6.5 nsec.
Immunofluorescence
HEK cells seeded on glass coverslips were fixed with 3%
paraformaldehyde in PBS and permeabilized with PBS containing
0.1% Triton X-100 and 3 mM MgCl2. Non-specific binding was
blocked by means of 3% BSA in PBS. The cells were then
incubated in the presence of a rabbit anti-4.1R primary antibody
(EPB41, Sigma-Aldrich), 1:400 dilution at 4uC overnight, followed
by an Alexa 555 donkey anti-rabbit antibody (1:200; Jackson
ImmunoResearch Europe Ltd., Suffolk, UK). The coverslips were
mounted in 90% glycerol/PBS, and acquired using a Leica TCS
SPE AOBS confocal microscope equipped with an ACS APO
40x/1.15 OIL objective (Leica Microsystems GmbH). In the case
of transfected cells, the samples were prepared 24 hours after
transfection.
In the case of the immunofluorescence experiments with siRNA
transfected HEK cells, ICln and 4.1R were separately immuno-
labelled in different specimens, to avoid the cross-reactivity of the
secondary antibody, since both primary antibodies were raised in
rabbit. Anti-rabbit Alexa 488 (Invitrogen) was used (1:200 dilution)
as secondary antibody in both cases. The same acquisition
parameters of the Alexa 488 signal were used both for ICln
siRNA and control siRNA samples. In the case of ICln
immunolabelling, cells were fixed with 3% paraformaldehyde in
PBS and permeabilized with PBS containing 0.1% Triton X-100
and 3 mM MgCl2. Non-specific binding was blocked by means of
3% BSA in PBS. The cells were then incubated with the anti-ICln
antibody (1:100 dilution) for 2 hours at room temperature,
followed by the secondary antibody. The coverslips were mounted
in 90% glycerol/PBS, and images were acquired using a Leica
TCS SP5 AOBS confocal microscope equipped with an HCX PL
APO 63x/1.4 OIL objective (Leica Microsystems GmbH). DNA
was stained with DAPI (49,6-diamidino-2-phenylindole).
Correlative light-scanning electron microscopy (CLEM)
HEK cells were transfected with the following plasmids: EGFP-
IRES (control), 4.1R135-IRES-EGFP, 4.1R80-IRES-EGFP,
4.1R135-IRES-EGFP and ICln-IRES-DsRED, 4.1R80-IRES-
EGFP and ICln-IRES-DsRED, ICln-IRES-DsRED. Twenty-four
hours post-transfection, the cells were seeded on micro-patterned
Aclar discs functionalised with Poly-L-Lysine. The pattern, which
consisted of an asymmetrical mesh of about 140 mm squares, was
sculpted on Aclar film using the pulsed laser of a micro-dissecting
microscope (Leica Microsystems GmbH) [51]. The coordinates
allowed the identification of the same cell by both fluorescence
microscopy and SEM.
The confocal images were acquired 48 hours post-transfection
using an HCX PL FLUOTAR 20x/0.5 objective (Leica Micro-
systems GmbH). After image acquisitions, the cells were fixed with
glutaraldehyde 1.2% in NaCacodylate 0.1 M for 1 h, and then
post-fixed with 1% osmium tetroxide (OsO4) in NaCacodylate
0.1 M for 1 h. The samples were gradually dehydrated by means
of an ethanol series, dried using a critical point drier (Emitech
K850, Quorum Technologies Ltd, East Sussex, UK), and
sputtered with gold (Polaron E5100 Sputter Coater, Quorum
Technologies Ltd.) before the transfected cells were imaged by
means of SEM (Zeiss Sigma Field Emission Scanning Electron
Microscope, 1 kV, SE2 detector). The images acquired from each
specimen in three independent experiments were used to measure
the area, number and length of filopodia by means of ImageJ
software.
Protein preparations
Total membrane proteins. Twenty-four hours after trans-
fection, the cells were collected by scraping, pelleted, resuspended
in PBS in the presence of a complete EDTA-free protease
inhibitor cocktail (Roche Diagnostics S.p.A., Milan, Italy),
followed by repeated passages through a 29G needle. Total
membrane proteins were extracted as described in [54], and
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protein concentrations were measured by means of a Bradford
assay. The reliability of membrane separation was verified by
confirming the enrichment of cadherin (a plasma membrane
marker) in the plasma membrane fraction and comparing it with
GAPDH, a cytosolic marker (data not shown).
In the case of the experiments using cells exposed to a hypotonic
challenge, the cells were exposed for 15 min to a slightly
hypertonic solution (in mM: NaCl 90, KCl 5, CaCl2 2, MgCl2
2, glucose 5, HEPES 10 and mannitol 100, 317 mOsm, pH 7.4) or
hypotonic solution (obtained by omitting mannitol from the
hypertonic solution), before being harvested and lysed.
Total protein extracts. The cells were lysed in Tris lysis
buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1%
NP40, Roche Diagnostics complete EDTA-free protease inhibitor
cocktail, pH 7) and snap-frozen in liquid nitrogen. The lysate was
spun at 4500 g for 5 minutes, and then the supernatant was saved
and stored at 280uC until use. Protein concentration was
quantified by means of a Bradford assay.
Western blotting
All of the protein extracts were heated at 99uC for 5 minutes in
SDS-PAGE solubilising buffer (58 mmol/L Tris HCl, 10%
glycerol, 2% SDS, 0.004% bromophenol blue, pH 6.8) containing
7.5% dithiothreitol. The proteins were separated by means of
SDS-PAGE electrophoresis on a 10% polyacrylamide gel, and
transferred to a PVDF membrane. After blocking, the membrane
was incubated with anti-ICln [5], anti-actin I-19 (Santa Cruz
Biotechnology, Dallas, Texas, USA), anti 4.1R C-16 (Santa Cruz
Biotechnology) or anti-4.1R EPB41 (Sigma-Aldrich), anti-EGFP
(Clontech), monoclonal anti-GAPDH (clone GAPDH-71.1, Sig-
ma-Aldrich), anti-pan cadherin ABT35 (Abcam plc, Cambridge,
UK), or anti-FLAG M2 antibody (Sigma-Aldrich), diluted in the
blocking buffer at 4uC overnight, followed by several washes, and
then by the secondary HRP-conjugated antibody. The Immobilon
ECL system (Millipore S.p.A., Vimodrone, Italy) was used for
detection.
The PVDF membrane was always stained using the amido
black staining procedure in order to assess the efficiency of protein
transfer and verify equal loading.
The bands were densitometrically analysed using the ImageJ
software.
Co-immunoprecipitation (co-IP)
FLAG-ICln co-IP. HEK cells co-transfected with pFLAG-
ICln (or pFLAG-BAP [Sigma-Aldrich] in the case of controls) and
4.1R-Y or Y-4.1R chimeras, were lysed in Tris lysis buffer (25 mM
Tris pH 8, 150 mM NaCl, 10% glycerol, Roche Diagnostics
complete EDTA-free protease inhibitor cocktail, 0.5% Triton X-
100), the cell debris were pelleted at 4500 g for 10 min (4uC), and
the supernatants (2 mg) were immunoprecipitated using 100 ml of
the anti-FLAG M2 affinity gel, a purified murine IgG1 anti-FLAG
antibody covalently attached to agarose beads (Sigma-Aldrich).
The bound protein complexes were eluted in the presence of
enriched 130 mg/mL FLAG peptide (Sigma Aldrich) in PBS buffer
in 40 mL aliquots, run on SDS-PAGE, and revealed by means of
Western blotting using anti-4.1R (16-C, Santa Cruz Biotechnol-
ogy) and anti-FLAG M2 antibodies (Sigma-Aldrich).
Actin co-IP. HEK cells transfected with 4.1R-IRES-EGFP
vectors (alone or co-transfected with C-ICln or CFP) were lysed in
CHAPS binding buffer (25 mM HEPES, 150 mM NaCl, 1 mM
MgCl2, Roche Diagnostics complete EDTA-free protease inhib-
itor cocktail, and 0.5% CHAPS). After repeated syringing through
a 20 gauge needle, the cell debris were pelleted at 4500 g for
10 min (4uC), and the supernatants (2 mg) were incubated at 4uC
overnight with 40 mL of agarose-bound actin (I-19) AC goat Ig-G
(0.5 mg/mL; Santa Cruz Biotechnology) or goat IgG-AC – agarose
(sc-2346; Santa Cruz Biotechnology) in the case of controls. The
bound protein complexes were eluted by resuspending the resin in
40 mL of 2X SDS-PAGE solubilising buffer, boiled for 5 min, and
pelleted at 10000 g for 1 min. The supernatants were assayed
(21 mL) by means of Western blotting using anti 4.1R 16-C and
anti-actin I-19 antibodies.
siRNA transfection
Scrambled siRNA (negative control) and validated ICln siRNA
were purchased from Invitrogen. siRNAs were co-transfected with
the ptdTOMATO-N1 vector (10:1 w/w) into HEK cells by using
Lipofectamine 3000 (Invitrogen), according to manufacturer
instruction. Cells were used for western blot or immunofluores-
cence experiments 48 hours after transfection.
Statistics
The data are expressed as mean values 6 standard error of the
mean. The differences between two groups were assessed using a
two-tailed Student’s t-test, and the differences among three or
more groups were assessed using one-way ANOVA (analysis of
variance) with Bonferroni’s or Dunnet’s multiple comparison post-
test. The groups were considered significantly different when at
least a 95% confidence level was obtained (p,0.05).
Results
ICln interacts with YFP-tagged 4.1R80 and 4.1R135 in HEK
cells
In HEK cells, both low molecular weight (LMW) or high
molecular weight (HMW) native 4.1R isoforms co-immunopre-
cipitated with the transfected C-terminally flagged ICln (FLAG-
ICln) (Fig. 1A).
We used FRET studies to investigate the in vivo sub-cellular
localisation of the 4.1R/ICln interaction, and the specific
relationship between ICln and 80 or 135 kDa isoforms, using
YFP-tagged 4.1R (Y-4.1R80 and Y-4.1R135) and CFP-tagged ICln
(C-ICln). In comparison with the control C/Y-4.1R80, the C-
ICln/Y-4.1R80 pair showed a statistically significant FRET signal
(Figs. 1B and 1C); there was no significant FRET signal with the
other FRET pair, Y-4.1R135/C-ICln (FRETeff C-ICln/Y-
4.1R135 = 1.7760.36, n = 26; FRETeff C/Y-4.1R135 = 0.836
0.38, n = 24, ns, t-test). The FRETeff calculated for Y-4.1R80
and a mutated C-ICln (C-IClnT) lacking the 4.1R binding site [8],
was not different from the control (FRETeff C-IClnT/Y-41R80
= 4.1660.89, n = 20; FRETeff C/Y-41R80 = 2.4260.89, n= 10,
ns, t-test), thus confirming the specificity of the interaction between
Y-4.1R80 and C-ICln.
We used co-immunopreciptation experiments to verify the
possibility of a 4.1R135/ICln interaction further (Figs. 1D and 1E).
HEK cells were co-transfected with a C-terminally flagged ICln
(FLAG-ICln) and the same 4.1R chimeras as those used in the
FRET experiments. Both the 4.1R fusion proteins strongly
immunoprecipitated with FLAG-ICln, thus suggesting that the
unfavourable position of the fluorophores might be the main cause
of the low FRET signals of Y-4.1R135.
ICln over-expression in HEK cells inhibits 4.1R membrane
localisation
Both 4.1R variants contain exon 16, which is essential for the
interaction with actin/spectrin [52] and nuclear targeting [36],
and exon 5, which is involved in membrane binding [53] and
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nuclear export [45]. The localisation of both the chimeric (Fig. 2A)
and native (Fig. 2B) 4.1R isoforms was consistent with the role of
the two exons insofar as the nuclear localisation of 4.1R135 was
reduced, which is in line with the reported inhibition of nuclear
targeting exerted by the HP region [45].
Confocal imaging of HEK cells over-expressing YFP-tagged
4.1R unequivocally showed that C-ICln inhibited the membrane
association of both Y-4.1R80 and Y-4.1R135 (Fig. 2A). The
reduced membrane localisation of both proteins was accompanied
by a cytoplasmic accumulation of 4.1R. This ICln-related effect
was observed regardless of the cell confluence degree, when the
untagged 4.1R proteins were over-expressed and labelled with the
anti-4.1R antibody, and when endogenous 4.1R was visualised
(Fig. 2B).
Western blot quantification showed that the membrane-bound
pool of both endogenous 4.1R isoforms was statistically decreased
by C-ICln over-expression (Fig. 2C). No significant effect was
detected in the case of cadherin, which was used as internal control
for the normalization of 4.1R signals in the quantitative analysis.
The Western blot experiments on total protein preparations
indicated that ICln did not significantly alter the global level of
4.1R expression (Fig. 2C).
To better characterise the physiological role of ICln in
regulating 4.1R localisation, we performed ICln knockdown
experiments (Fig. 3). siRNA for ICln and control scrambled
siRNA (siRNA ctrl) were co-transfected in HEK cells together with
the fluorescent protein tdTomato, to identify the cells where ICln
was downregulated (Fig. 3A, first row). Both in immunofluores-
cence (Fig. 3A) and western blot experiments (Fig. 3B), the ICln
downregulation in cells transfected with siRNA ICln was clearly
evident. It should be noted that, due to different expression levels
of the fluorescent protein, the cells with low tdTomato levels are
not visible in the images. Endogenous 4.1R protein localized in
membrane regions both in cells with low expression levels of ICln,
and in cells transfected with the control siRNA. However, we
observed in two independent experiments that the 4.1R
membrane signal was globally more intense in the siRNA ICln
sample.
ICln inhibits 4.1R interactions with sub-membranous
actin
We investigated whether ICln affects the integrity of the 4.1R/
actin/spectrin ternary complex in cell cortical regions. FRET
experiments performed to investigate the influence of ICln on
4.1R/actin interactions (Fig. 4) showed that, like the 4.1R135
signal, CFP-tagged ß-actin (C-ßactin) localised in the cytoplasm
and sub-membrane regions. For this reason, FRET efficiency was
measured separately in ROIs of the whole cytoplasm and ROIs of
only the thin cytoplasmic layer underlying the plasma membrane
(Fig. 4B). This analysis did not include 4.1R80 because its FRETeff
was no different from that of the control (over-expression of YFP/
C-ßactin/IRES-DsRED). The transfected cells showed a low
FRET signal that was mainly concentrated in the membrane area.
In comparison with the control condition, the cells expressing
Figure 1. 4.1R80/135 and ICln interactions in HEK cells: co-immunoprecipitation and FRET. (A) Co-immuprecipitation of FLAG-ICln and
endogenous 4.1R in HEK cells. Anti-4.1R (4.1R) and anti-FLAG (FLAG) were respectively used to detect 4.1R and FLAGed proteins. Western blot
showing immunoprecipitation of 4.1R with Flag-ICln, but not FLAG-BAP (control). (B) Images of an acceptor photobleaching FRET experiment using
living cells over-expressing Y-4.1R80 and C-ICln. Pre-photobleaching (PRE pb) and post-photobleaching (POST pb) images are shown. Scale bar:
10 mm. (C) Quantification of FRET experiments with CFP-tagged ICln and YFP-tagged 4.1R80. The mean FRETeff 6 SEM is plotted (*p,0.05 for Y-
4.1R80+C-ICln vs Y-4.1R80+C; one-way ANOVA). The numbers inside the bars represent the number of cells analysed from at least 3 independent
experiments. (D) Co-immunoprecipitation of Y-4.1R80 or (E) Y-4.1R135 with FLAG-ICln (ICln) or FLAG-tagged bovine alkaline peroxidase (BAP, control).
The HEK cells were co-transfected with C-terminally FLAGed ICln and Y-4.1R80 or Y-4.1R135. FLAG-ICln was immunopurified using an anti-FLAG
antibody. The 4.1R signal (anti-GFP antibody) and FLAG signal (anti-FLAG antibody) in cell lysates (L), and three sequential 40 ml eluates (E1-E3) are
shown for all conditions.
doi:10.1371/journal.pone.0108826.g001
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Figure 2. ICln over-expression affects 4.1R membrane localisation. (A) The images in the first row show the intracellular localisation of the
indicated proteins (single confocal planes); the unshown co-transfected protein is indicated in brackets. The images in the second row are
enlargements of the insets indicated in the first row images. (B) Exemplificative images of HEK cells co-transfected with GFP-IRES-4.1R80 (4.1R80) or
GFP-IRES-4.1R135 (4.1R135) and CFP (C) or CFP-ICln (C-ICln) vectors. The samples were immunolabelled with an anti-4.1R antibody to visualise the 4.1R
signal. In the panels showing the endogenous 4.1R signal, the asterisks indicate the CFP or C-ICln transfected cells. Scale bar 10 mm. (C) Effect of ICln
on endogenous 4.1R membrane localisation: Western blot of total membrane protein extracts (left) and total endogenous 4.1R (right) from HEK cells
transfected with C-ICln or C (control). The histograms show the mean OD value of the 4.1R signal normalised for the corresponding cadherin (left) or
tubulin (right) signal (n = 4). The values are percentages of the control. **p,0.01; *p,0.05.
doi:10.1371/journal.pone.0108826.g002
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Y-4.1R135/C-ßactin showed a statistically significant FRET in the
membrane region (control FRETeff = 0.7960.41, n = 8; p,0.01)
in the absence of ICln over-expression; when ICln was co-
expressed, FRETeff decreased to control levels. No significant
FRET was observed in the cytoplasm regardless of the presence or
absence of ICln (Fig. 4B).
Immunoprecipitation experiments performed upon the over-
expression of both 4.1R and C-ICln (or CFP, control) using an
anti-actin antibody (Figs. 4C and 4D) confirmed that the presence
of ICln tends to reduce the amount of both 4.1R isoforms in actin
immunoprecipitate and, in line with the results of the FRET
experiments, this effect was more marked in the case of 4.1R135.
4.1R80 (but not 4.1R135) enhances the hypotonically
induced ICl,swell current
ICln plays a major role in the activation of ICl,swell, a key player
of regulatory volume decrease (RVD). Whole-cell patch-clamp
experiments were performed to study the functional effects of
4.1R/ICln interactions on the regulation of the ICl,swell current
(Fig. 4). HEK cells transfected with 4.1R135/80 were initially
maintained in a hypertonic solution (Figs. 5A, 5D and 5E) but,
when this was replaced by a hypotonic solution, an outward
rectifying current was activated. The reversal potential was not
statistically different from 0 mV, as expected for a chloride
current, and the current was slightly inactivated at potentials
higher than +60 mV (Figs. 5A and 5B). All of these characteristics
are in line with those of the swelling-activated ICl,swell current [54].
The cells transfected with 4.1R80 (but not those transfected with
4.1R135) showed a statistically significant higher current not only
when the hypotonic current was fully activated (Fig. 5B), but also
when the basal current was measured under hypertonic conditions
(Fig. 5D). Transfection with 4.1R135 induced a hypotonically
activated current that was not statistically different from the
control (Fig. 5B). These findings are in line with the time course of
current activation (Fig. 5C), which showed that 4.1R80 activated
the current more rapidly than both the control and 4.1R135, while
Figure 3. Downregulation of ICln by siRNA and 4.1R membrane localisation. (A) Exemplificative images of HEK cells co-transfected with the
ptdTOMATO-N1vector and scrambled (ctrl) or ICln siRNA (ICln). The samples were immunolabelled with an anti-4.1R antibody (4.1R) or anti-ICln
antibody (ICln). Scale bar 20 mm. (B) Western blot of total protein extracts from HEK cells co-transfected with ICln siRNA (ICln) or scrambled siRNA (ctrl)
and the fluorescent tdTomato protein. The histograms show the mean OD value of the ICln signal normalised for the corresponding GAPDH signal
(n = 4). The values are percentages of the control. **p,0.01.
doi:10.1371/journal.pone.0108826.g003
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4.1R135 significantly inhibited current activation in comparison
with the control.
In hypotonically exposed HEK cells, the amount of 4.1R in
the plasma membrane decreases and the 4.1R80/ICln
interaction increases
It is known that ICln translocates to membrane regions upon
hypotonic challenge [11,49]. To investigate the dynamics of 4.1R
interactions with the plasma membrane during a hypotonic shock,
we analysed the co-localisation of the membrane marker CFP-
mem (Cm) and the over-expressed YFP-tagged 4.1R (Figs. 6A, 6B
and 6C). Pearson and Manders coefficients were measured in the
same cells during exposure to the hypertonic extracellular solution,
and 5 and 10 minutes after switching to a hypotonic solution
(Figs. 6B and 6C). The overall co-localisation (represented by
Pearson’s coefficient, Fig. 6B) of 4.1R135 and Cm significantly
decreased in the hypotonic solution and, accordingly, so did the
fraction of 4.1R135 overlapping Cm (Manders coefficient, Fig. 6C).
The control cells were co-transfected with Cm and YFP-mem
(Ym).
In line with the co-localisation data, Western blots of the
membrane proteins of HEK cells showed a reduction in the
amount of membrane-associated 4.1Rs that was significant only in
the case of the 135 kDa isoform (Fig. 6D).
These results suggest that a hypotonic shock partially detaches
4.1R proteins from the plasma membrane, and has a greater effect
on the 135 kD isoform.
In order to study the 4.1R/ICln interaction upon cell swelling,
we performed sensitised emission FRET experiments using Y-
4.1R80/C-ICln and Y-4.1R80/C (Fig. 6E) that allowed us to follow
the time-course of the 4.1R80/ICln interaction during hypotonic
exposure. Analogous experiments could not be performed with the
135 kDa isoform, since no significant FRET signal could be
detected with Y-4.1R135/C-ICln pair, as previously reported.
The NFRET values (Fig. 6E) indicate that hypotonicity
significantly increased the interaction between C-ICln and Y-
4.1R80, starting after five minutes of hypotonic challenge. The
NFRET values in the controls (Y-4.1R80/C) were no different
from those recorded under hypertonic conditions, thus demon-
strating the specificity of the ICln/4.1R80 response to hypotonicity
(Fig. 6E). These results were confirmed by the acceptor photo-
bleaching experiments in which the FRETeff calculated in the Y-
4.1R80/C-ICln-expressing cells exposed to the hypertonic extra-
cellular solution significantly increased after 10 min exposure to
the hypotonic solution (FRETeff = 11.6260.86, n = 40, in the
hypertonic solution vs FRETeff = 15.0761.17, n= 20, in the
hypotonic solution; p,0.05).
ICln over-expression antagonises the cell spreading and
filopodia emission promoted by 4.1R135 over-expression
Actin plays an important role in regulating cell spreading [55]
and filopodia emission [56,57], and 4.1 proteins regulate cell
adhesion and spreading in mouse keratinocytes [58] and astrocytes
[59]. As ICln seemed to affect the membrane and actin binding
Figure 4. FRET analysis of YFP-tagged 4.1R and CFP/b-actin (C- bactin) interaction. (A) Example of an acceptor photobleaching FRET
experiment in HEK cells over-expressing Y-4.1R135 and C-bActin. A FRET signal can be seen under the plasma membrane (asterisks). Scale bar 5 mm.
FRETeff was measured in ROIs in the plasma membrane or cytoplasm. (B) Mean FRETeff 6 SEM in cells over-expressing Y-4.1R135, C-bActin and IRES-
DsRED (-ICln) or Y-4.1R135, C-bActin and ICln-IRES-DsRED (+ICln). ***p,0.001, -ICln vs +ICln. (C, D) Co-immuprecipitation of over-expressed 4.1R80 or
4.1R135 and actin. (C) HEK cells were transfected with GFP-IRES-4.1R80/135, and actin was immunoprecipitated using a goat anti-actin antibody
(samples 135 or 80). Goat Ig-G (bovine alkaline peroxidase) was used as a negative control (ctr). (D) C-ICln (+ICln) or C (-ICln) was co-transfected with
4.1R to investigate the effect of ICln on 4.1R/actin interactions. The Western blots are representative of three (4.1R135) or two (4.1R80) independent
experiments, all with comparable results. The 4.1R (anti-4.1R) and actin signals (anti-Act) in the cell lysates (L) and final eluates (E) are shown for all
conditions. The additional bands in the 4.1R80 Western blot in D are probably residual incompletely denatured (anti-4.1R blot) or denatured (anti-
actin blot) antibody chains as they were also recognised by the sole secondary anti-goat antibody.
doi:10.1371/journal.pone.0108826.g004
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properties of 4.1R, we investigated whether it also interfered with
these functions.
A qualitative evaluation of confocal Z-stack acquisitions
indicated that the cells transfected with YFP-tagged 4.1R were
larger and that 4.1R induced the growth of an increased number
of filopodia, a phenotype that was more pronounced with the
over-expression of 4.1R135 (Fig. 7A). This phenotype was com-
pletely reverted when C-ICln was co-expressed in HEK cells
(Fig. 7A). A correlative-light scanning electron microscopy
(CLEM) protocol was established in order to measure the cell
area and the number and length of the filopodia (Fig. 7C). We
used high-resolution electron microscopy because the thickness of
filopodia is below the resolution limit of conventional confocal
microscopy [57], as confirmed by super-resolution gated-stimu-
lated emission depletion (g-STED) microscopy (Fig. 6B) [60].
Moreover, the detachment of fluorescent 4.1R from the plasma
membrane caused by the presence of ICln (Fig. 2) could lead to an
underestimate of the number of filopodia when measured by
means of standard confocal microscopy (Fig. 7A).
The SEM analysis (Fig. 7D) confirmed that 4.1R135 over-
expression induced a significant increase in cell surface area, but
co-expression with ICln reverted this phenotype. The over-
expression of 4.1R80 induced a smaller increase that was not
statistically different from that of EGFP-expressing cells, but still
significantly greater than that measured when ICln was co-
expressed.
We also considered the density of the filopodia protruding from
the cell profile: i.e. the number of filopodia per cell/cell perimeter
(Fig. 7E). In comparison with the control EGFP-expressing cells,
the over-expression of 4.1R135 induced a significant increase in
filopodia density, an effect that was once again reverted by the co-
expression of ICln.
The over-expression of 4.1R80 did not significantly affect
filopodia density, thus suggesting that the two isoforms play a
similar but not identical role in dynamically regulating the cortical
Figure 5. ICl,swell characterisation in cells over-expressing 4.1R
80/135. (A) Representative whole-cell traces recorded in control cells (over-
expressing GFP) or cells over-expressing the 4.1R80 or the 4.1R135 protein exposed to hypertonic (Hyper) and hypotonic (Hypo) extracellular solutions.
(B) Relationship between mean current density, d (pA/pF), and membrane voltage, V (mV), in cells over-expressing the indicated proteins and exposed
to the hypotonic extracellular solution for 10 min (GFP: n = 22, 4.1R80: n = 15, 4.1R135: n = 14). (C) Chloride current activation during hypotonic
exposure (GFP: n = 24, 4.1R80: n = 17, 4.1R135: n = 14. (D,E) Relationship between mean current density and membrane voltage in control cells or cells
over-expressing the 4.1R80 (C) or the 4.1R135 protein (D) in the hypertonic extracellular solution (GFP: n = 43, 4.1R80: n = 38, 4.1R135: n = 27. *p,0.05;
***p,0.001. Two-way ANOVA.
doi:10.1371/journal.pone.0108826.g005
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cytoskeleton. No significant difference in the length of the
protrusions could be detected (not shown).
Discussion
ICln interactions have so far only been reported with 4.1R80
variants or single 4.1R domains [8,22,61]. Our co-immunopre-
cipitation results show that ICln interacts with both the 80 and
135 kDa isoforms of native and over-expressed chimeric 4.1R.
The FRET experiments demonstrated the direct interaction
between ICln and 4.1R80, although the co-immunoprecipitation
experiments clearly indicated interactions with both the chimeric
variants. This apparent incongruity may have been due to the
unfavourable and rigid orientation of the fluorophore dipoles in
the complex, or the small Fo¨rster radius (R0) of the CFP/YFP
FRET pair (4.72 nm) [62].
One of the main effects of ICln co-expression was a change in
the subcellular localisation of both 4.1R proteins. In co-expression
with C-ICln both 4.1R proteins were mislocalized: 4.1R binding
Figure 6. Hypotonic shock affects the membrane localisation of 4.1R, and promotes the 4.1R/ICln interaction. (A) Single confocal plane
of a cell expressing the membrane marker CFP-mem (Cm) and the Y-4.1R135 protein acquired in the hypertonic (hyper) and hypotonic (hypo 109)
extracellular solutions. The arrows indicate the membrane regions in which the 4.1R135 signal greatly decreases after hypotonic exposure. The mean
Pearson (B) and Manders coefficients (C) between Cm and the YFP-tagged proteins indicated in the graphs were calculated from the Z-stacks. The
Manders coefficient represents the fraction of the YFP signal overlapping the CFP signal. For each sample, the mean coefficients obtained in
hypertonic extracellular solution were compared with the mean coefficients obtained under hypotonic conditions (ANOVA with Dunnett’s post-hoc
multiple comparison test; *p,0.05). Scale bar 10 mm. (D) Western blot of endogenous 4.1R in total membrane preparations of HEK cells under
hypertonic (hyper) or hypotonic (hypo) conditions. The related graph shows the mean OD of the 4.1R bands normalised for those of the Na/K pump
(OD4.1R/ODNaK) (n = 8) used to quantify the changes. The values are percentages of the hypertonic condition. *p,0.05. (E) Representative NFRET
images of Y-4.1R80/C-ICln expressing cells in the hypertonic extracellular solution or after 10 min exposure to the hypotonic extracellular solution, and
the NFRET time course during RVD. In comparison with the hypertonic condition, the NFRET signal in the Y-4.1R80/C-ICln expressing cells (but not the
control Y-4.1R80/C expressing cells) significantly increased after five minutes in the hypotonic extracellular solution (one-way ANOVA with Dunnett’s
multiple comparison test). The NFRET values of the Y-4.1R80/C-ICln expressing cells in the hypertonic extracellular solution were statistically different
from those of the control Y-4.1R80/C cells (t-test) after both 0 (hypertonic) and 10 min hypotonic solution exposure. Scale bar 10 mm. ***p,0.001;
**p,0.01.
doi:10.1371/journal.pone.0108826.g006
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to the membrane and to the cortical actin cytoskeleton was
inhibited and the cytoplasmic pool was increased, as shown in the
immunofluorescence images. No variation in the total amount of
4.1R was detected, supporting the hypothesis that the reduction of
the membrane pool was not a consequence of protein degradation
or of a change in global expression levels. It is feasible that the
effects of ICln binding under physiological condition are less
dramatic, but it is anyway likely that ICln is one of the factors that
negatively affect 4.1R membrane localization, an effect that could
be artificially emphasized, but not artificially created, by ICln
over-expression. The qualitative evaluation of 4.1R localisation in
cells with downregulated ICln is in accordance with such a
physiological role of ICln.
One important observation concerning the mechanism by
which ICln inhibits the membrane association of 4.1R is that ICln
interacts directly with the FERM domain, which is crucial for the
association itself and the target of complex regulation [39,40]. ICln
binds to its C-lobe, which also binds to the cell adhesion molecule
CD44, phospholipid phosphatidylserine [63] and, together with
lobe A, forms a binding site for the cytoskeletal adapter protein
p55 [53] and the lipid phosphatidylinositol-4,5-bisphosphate
(PIP2), which can also influence actin binding [64]. By interacting
with this crucial domain, ICln might alter the affinities for other
binding partners, thus inhibiting the association of 4.1R with the
cortical actin cytoskeleton and greatly affecting its role in the
recruitment of a wide range of proteins involved in signalling [65-
67], adhesion [58,68] and ion transport [18,28–30].
It is worth mentioning that the C-terminal lobe of the FERM
domain is a PIP2 binding PH (pleckstrin homology) domain [69];
ICln binds to it with its unstructured C-terminal half, leaving its N-
terminal half (which is also a PH domain) [70,71] free to interact
with other potential partners. The PH domain of ICln does
not have the electrostatic surface polarisation characteristic of
PIP2-binding [71] PH domains, and so it could radically change
Figure 7. Morphological analysis of HEK cells over-expressing 4.1R and ICln. (A) The maximum projections of a number of optical sections
over-expressing the indicated proteins and covering at least half of the cell (z-step size 0.25 mm). Only the YFP channel is shown. Scale bar: 20 mm. (B)
The confocal plane of the cell attached to the coverglass acquired using the confocal or gated-STED (g-STED) module of a Leica TCS SP8. The cell
over-expressed a membrane marker (YFP-mem) and the 4.1R135 protein. Only the YFP signal is shown. Scale bar is 5 mm, and 0.5 mm in 1 and 2. (C)
Example of SEM acquisitions of cells transfected with GFP-IRES-4.1R135; the lower image is the magnified view of the inset, and makes it possible to
see the mesh of cellular filopodia. Scale bar 10 mm (5 mm in the inset). (D) The histogram shows the mean cell area 6 SEM (mm2) calculated from the
SEM images. (E) The mean density of filopodia per cell (the number of filopodia per cell/cell perimeter (mm)). The numbers in the bars represent the
number of analysed cells from three independent experiments. *p,0.05; ***p,0.001.
doi:10.1371/journal.pone.0108826.g007
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the affinity of 4.1R for PIP2 and, consequently, its interaction
pattern.
It has already been shown that 4.1R localisation can be
regulated by its interaction with other proteins [68], suggesting
that the formation of functional protein complexes is essential for
proper 4.1R intracellular localisation and function. ICln-4.1R
interaction could represent a way of modulating 4.1R function, by
favouring the formation of specific protein complexes in specific
subcellular compartments of the cell. One of the main functions of
4.1R proteins is their regulation of membrane transport systems.
The 4.1R modulation of erythrocyte Cl-/HCO3
- anion exchanger
1 (AE1) has been clearly documented [41,61,72], and many other
ion channels and transporters have been added to the list more
recently [18,73]. In particular, it has been suggested that 4.1R may
be involved in volume regulation as it has been shown that it
physiologically down-regulates Na+/H+ exchange (which is
involved in the process of regulatory volume increase, RVI), and
that up-regulation of Na+/H+ exchange is an important contrib-
utor to the high cell Na+ content of 4.12/2 mouse erythrocytes
[18,29]. Our findings show that 4.1R80 can activate ICl,swell, which
is involved in RVD, thus suggesting that 4.1R may be a crucial
factor linking the complex parallel regulation and synchronisation
of the transport systems participating in cell volume regulation,
which is related to various other cell housekeeping functions such
as cell morphology and proliferation [74,75].
Our data concerning the mechanism by which 4.1R80 activates
the ICl,swell current are not conclusive, but it has been previously
reported that 4.1R or other 4.1 isoforms have a direct effect on
Na+, Cl-, K+ and Ca2+ currents [30,73], and that this has
important consequences for cardiac pathology [30,76] and nerve
conduction [77–79]. It has also been suggested that the 4.1
proteins may regulate the membrane expression of these transport
systems [73,80]. However, the picture is particularly complex in
the case of ICl,swell because the identity of the channel protein is
still debated [81,82], although the translocation of ICln towards
the membrane is considered to be one of the key processes of
ICl,swell activation [11,49]. The relation between ICln and the
channel responsible for ICl,swell is far from being understood. It has
been proposed that it could be one of the molecular components of
the channel itself [83], yet not all agree [82,84] on this hypothesis.
Even if reconstitution of pure ICln proteins in artificial bilayers
can result in the conduction of an ion current [83,85], it has been
demonstrated that, in mammalian cells, the association of ICln
with the membrane is typical of an extrinsic protein rather than an
integral protein [86]. Accordingly, it has been proposed that ICln
might be a key regulator of a still unknown channel; its
translocation towards the membrane area would be necessary to
activate the current, maybe through integrin-related pathways
[87], and/or by its interaction with subcortical actin cytoskeleton
[14]. Along this line of thought, it is possible that ICln
translocation could play a role in the reorganization of the actin
cytoskeleton by inhibiting the 4.1R bridging function between the
plasmalemma and the subcortical actin ring, and this could be a
key event for the activation of the channel.
A complex reorganisation of the actin cytoskeleton during
hypotonicity has been reported [14,88-90], and it has been
proposed that different cell pools of F-actin (cortical, associated
with stress fibres, perinuclear) are involved in regulating swelling-
activated channels, possibly with different effects [91]. Our data
show that ICln co-expression inhibits the association of 4.1R with
the membrane, and that its relocation is associated with
detachment from the cortical actin cytoskeleton. It is therefore
possible that hypotonicity-induced ICln translocation to the sub-
membranous region plays a role in the detachment of 4.1R from
the membrane and cortical actin cytoskeleton, and that this is one
of the steps leading to ICl,swell activation. A second factor affecting
4.1R membrane affinity during hypotonicity might be calcium as a
calcium transient is a common early event in RVD signalling
[92,93]. The fact that the membrane association of 4.1R135 seems
to be more affected by hypotonicity may reflect its greater
sensitivity to calcium signalling [35].
These events could participate in the rearrangement of the sub-
cortical actin cytoskeleton that accompanies the activation of
ICl,swell and coincides with increased interaction between ICln and
actin [14]. The complex of ICln and 4.1R (and maybe other
partners) seems to restrict the presence of both proteins to the
cytosol, thus reducing their abundance in other sub-cellular pools
and possibly modulating 4.1R function.
The fact that the over-expression of 4.1R80, but not 4.1R135,
results in the activation of the current was unexpected but it could
suggest that the ratio between the two 4.1R isoforms in the
membrane area is a key factor for the activation of the current and
ICln could play a role in this process. Others have previously
reported differences in the functions and behaviour of the various
4.1R isoforms, such as their binding affinities for membrane
proteins [35], and it is likely that the HP region plays a critical role
in conferring specific functions to each isoform. It is possible that
regulating the ratio between 4.1R80 and 4.1R135 (rather than the
absolute quantity of individual proteins) in the membrane area is
crucial for the correct functioning of the sensing and signalling
events linking hypotonicity to RVD and for the activation of the
ICl,swell current. In accordance, during RVD we observed (by
western blot) a trend to the decreasement of the 4.1R135/4.1R80
ratio in total membrane preparations (in hypertonic condition:
4.1R135/4.1R80 = 1.7960,32, n= 11, in hypotonic condition:
4.1R135/4.1R80 = 1,1860,18, n = 12, p = 0.098), even if the result
was not significant. This observation agrees well with the co-
localisation and western blot data indicating that the hypotonicity
induced detachment from the membrane is more pronounced for
4.1R135 rather than 4.1R80. 4.1R80 over-expression could mimic
such a condition and could be responsible for the increased ICl,swell
current we measured in hypertonic conditions.
In any case, the emerging picture is that the two isoforms can
have different functions and different effects on cell physiology. On
the basis of our data, 4.1R135 seems to be the main isoform
involved in regulating cell adhesion and filopodia emission; it is
possible that, by maximising these consequences on cell morphol-
ogy, its over-expression interferes with hypotonicity-related
signalling. ICl,swell activation has previously been related to actin
cytoskeleton stiffness [94,95], and it is feasible that, by inducing a
change in actin cytoskeleton architecture, the change in morphol-
ogy maximised by 4.1R135 negatively affects or at least slows down
ICl,swell activation. The fact that ICln, which usually causes
activation of the current [96], can inhibit all 4.1R135- related
changes in morphology is consistent with the hypothesis that this
functional specialisation of 4.1R135 may be critical for ICl,swell
activation.
Our findings indicate that cell spreading and the number of
filopodia are the microscopic cell features mainly affected by 4.1R
over-expression, and that ICln can revert these 4.1R-related
effects. It is reasonable to hypothesise that this phenotype is related
to the role of 4.1R in organising the actin cytoskeleton [56,57] by
directly binding to F-actin [25], and/or as a consequence of its
interaction with integrins at focal adhesions [58], thus leading to
the subsequent activation of a signalling pathway that leads to
actin reorganisation. It is conceivable that ICln binding interferes
with this process by inhibiting the association of 4.1R with
the plasma membrane cytoskeleton. Interestingly, it has been
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demonstrated that ICln can bind integrins in platelets [87,97], thus
supporting the hypothesis that an integrin-activated pathway may
be involved in important cell functions such as cell migration,
invasion, survival and proliferation [98–100]. An alternative or
additional possibility is that PKC might as well be involved in the
cross-talk between 4.1R and ICln. The PH domain of ICln
interacts with and can be phosphorylated by PKC in vitro [71].
PKC has also been reported to modulate swelling activated
currents [101–103] and is one of the modulators of 4.1R binding
to the membrane and the spectrin-actin [39,41] complex, with a
significant impact on membrane mechanical stability [39] and
deformability [104] and on the regulation of transport systems.
Our findings confirm that 4.1R plays a role in regulating cell
spreading. They also show that the co-expression of ICln can
revert the observed effects of 4.1R, thus confirming the hypothesis
that it acts as a modulator of 4.1R functions and affects the
regulation of a variety of membrane channels/transporters, the
organisation of signalling systems and the processes of cell division,
migration and differentiation.
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